# Auditing Patient Leakage, Cross-Platform Reproducibility, and Basal-Squamous Plasticity in Pancreatic Ductal Adenocarcinoma: A Multi-Cohort NCBI GEO Doctoral Synthesis

            Doctoral Dissertation Manuscript | Computational Oncology & Transcriptional Biomarker Auditing
            **Candidate Manuscript:** Arnab Mondal  |  Independent Translational Oncology Investigation (Based on Audited NCBI GEO Cohorts)
            Data Anchor: 1,791 Indexed Human PDAC GEO Series (2006 to 2026) | Discovery & External Validation Across N = 1,038 Arrays and RNA-Seq Profiles
            
              Date: November 21, 2026
              Reporting Standards: STROBE / TRIPOD [22]
              Matched Tech Bridge: r = 0.918 (n = 128)
              Companion Portal: pdac-geo-phd.pages.dev
            
          

          
            Structured Abstract
            **Background:** Pancreatic ductal adenocarcinoma (PDAC) carries a five-year relative survival of approximately 13% alongside steadily rising global incidence [1,2]. Despite 1,791 public human PDAC series in the NCBI Gene Expression Omnibus (GEO), automated browser workflows such as default GEO2R and secondary multi-cohort meta-analyses routinely yield irreproducible signatures due to unlogged intensity matrices, duplicate array inflation, uncalibrated two-channel baselines, spreadsheet metadata drift, and unrecognized patient reuse across array and RNA-sequencing deposits [7,8,9,13,18].

            **Methods:** We surveyed global human PDAC GEO deposition (2006 to 2026; 1,791 total series, 143 curated cohorts) and performed an end-to-end methodological audit across six primary clinical series spanning Affymetrix (GPL6244, GPL570), Agilent two-channel (GPL20769), custom microarray (GPL15048), and Illumina RNA-sequencing (GPL24676; N = 1,038 raw profiles, N = 769 strictly non-overlapping specimens). Fixing Discovery GSE183795 (N = 244; 134 tumors with survival) without peeking into external cohorts, we constructed an L2-regularized 10-gene diagnostic classifier and a frozen 10-gene Cox prognostic model (penalizer = 0.25), then evaluated blind cross-platform diagnosis with Decision Curve Analysis [21], Bland-Altman cross-technology agreement, leakage-titration Monte Carlo bias curves, Leave-One-Cohort-Out (LOCO) survival generalization (N = 230 pooled external patients, 161 deaths), and site-matched organ metastasis decontamination.

            **Results:** Programmatic intersection revealed pervasive cross-study patient overlap: GSE62452 (90/130 arrays matching all 45 patient E-IDs) and GSE28735 (45 pairs) are subsumed within GSE183795, while 131 of 175 bulk RNA-seq tumors (74.9%) in GSE224564 reuse the exact German-1/2/3 and UMD-1 discovery patients, leaving only 44 independent UMD-2/3 RNA-seq tumors. Auditing also rescued unlogged MAS5 intensities in GSE16515 (maximum 65,045), merged replicated paired arrays in GSE15471 (+26 empirical Bayes DEGs recovered via paired blocking), and flagged six Excel date-corrupted grading entries ('3-Feb') inside GSE183795. Across 13,556 shared genes (r = 0.709 to 0.847), weighted Stouffer integration isolated 433 upregulated and 132 downregulated consensus markers pairing extreme extracellular matrix desmoplasia (29/32 genes, OR = 313.9) with near-total exocrine acinar loss (17/18 genes, OR = 1,984.3). Frozen 10-gene diagnostic discrimination transferred onto blind external cohorts with ROC AUCs of 0.9421 (GSE15471), 0.9549 (GSE16515), and 0.8883 (GSE71729), while intercept recalibration eliminated Agilent baseline offset (specificity 0.000 to 0.935, Brier 0.170 to 0.119) and produced positive net clinical benefit. On prognostic survival, naive evaluation of unaudited GSE224564 inflated the hazard ratio by 85% (HR = 2.591, p = 4.07e-7 vs HR = 1.370 at 0% overlap in Monte Carlo titration), even as 128 matched patients verified high microarray-to-RNA-seq fidelity (r = 0.9180, Lin's CCC = 0.9178, Cohen's kappa = 0.8125). Restricting validation strictly to 230 de-leaked external patients confirmed significant generalization (median OS 16.17 vs 22.00 months, Log-Rank p = 0.0184, Stratified HR = 1.396, 95% CI 1.019 to 1.913, p = 0.0378). Independently, the locked risk score classified Basal-like vs Classical PDAC (AUC 0.8096 RNA-seq; 0.8341 Agilent; SERPINB3-High Cohen's d = +0.941) without stromal bias (p = 0.234) and separated liver PDAC metastases from site-matched normal liver parenchyma (Cohen's d = +1.787, AUC = 0.8844, p = 2.10e-6).

            **Conclusions:** Enforcing programmatic identity auditing, paired blocking, and threshold recalibration prevents spurious multi-cohort biomarker overfitting, separates realistic out-of-sample prognostic generalization (HR = 1.40) from leakage artifacts (HR = 2.59), and establishes a translational bridge linking epithelial mitotic-vesicular proliferation and ITGA3-anchored Basal plasticity directly to hepatic metastasis.

            **Keywords:** Pancreatic Ductal Adenocarcinoma | NCBI Gene Expression Omnibus | Data Leakage Audit | GEO2R Critique | Cross-Platform Agreement | Decision Curve Analysis | Basal-Squamous Plasticity | Doctoral Dissertation
          

          
        

        
        
          
## 1. Introduction

          Pancreatic ductal adenocarcinoma (PDAC) represents over 90% of exocrine pancreatic malignancies and remains projected among the leading causes of cancer-related mortality worldwide, with an overall five-year relative survival rate near 13% [1,2]. Late clinical presentation, early micro-dissemination prior to radiographic detection, and profound intratumoral cellular heterogeneity limit curative surgical resection to fewer than one in five patients. Over two decades of genomic profiling across international surgical consortia, however, transcriptional classification has established two dominant epithelial tumor programs: an endodermal, well-differentiated Classical subtype and a poorly differentiated, squamous-like Basal subtype associated with treatment resistance and shortened overall survival [3,4,5,6]. Separating tumor-intrinsic lineage state from an abundant desmoplastic cancer-associated fibroblast stroma remains central to translating transcriptomic classifiers into clinically reliable assays [4,6].

          Public archives housed at the National Center for Biotechnology Information Gene Expression Omnibus (NCBI GEO) contain more than 1,700 human pancreatic cancer series published between 2006 and late 2026. This rapid expansion, catalyzed by single-cell, spatial, and multicenter bulk RNA sequencing, creates broad empirical opportunity for high-powered biomarker discovery while simultaneously exposing a widespread crisis in secondary computational reproducibility. Interactive point-and-click pipelines such as default GEO2R [14,16] execute differential expression contrasts cleanly on single well-annotated comparisons, yet naive application across pooled multi-cohort analyses silently violates core statistical assumptions. In routine secondary literature, investigators often ingest raw unlogged microarray intensities alongside log-transformed series, treat technical duplicate microarrays as independent patient replicates, accept spreadsheet-corrupted clinical attributes such as date-mangled histologic grades [18], or evaluate cross-platform signatures without checking whether validation repositories merely re-sequence biological specimens already analyzed in discovery sets [7,8,9,13].

          Unrecognized patient leakage across discovery microarray cohorts and newer RNA-sequencing deposits acts as a particularly pernicious confounder. Because flagship surgical biobanks continuously expand longitudinal collections by adding RNA sequencing or updated Affymetrix chips to stored frozen tissue from earlier studies, an investigator training a Cox proportional hazards model [24] on one GEO accession and validating on a seemingly recent RNA-seq accession may inadvertently evaluate the same human tumors twice. Without formal sample-identity intersection prior to modeling, inflated hazard ratios and miniature log-rank p-values can masquerade as biological generalization when they largely reflect patient-level data memorization [22].

          This doctoral investigation addresses both the methodological failure modes and the underlying epithelial biology of PDAC across four integrated contributions anchored rigorously in audited NCBI GEO data. First, we map the global 2006 to 2026 PDAC GEO deposition trajectory and benchmark an upgraded, defect-corrected statistical pipeline against default GEO2R defaults. Second, using deterministic accession matching and full-transcriptome correlation checks across six prominent clinical datasets (`GSE183795`, `GSE62452`, `GSE28735`, `GSE15471`, `GSE16515`, `GSE71729`, `GSE57495`, and `GSE224564`), we expose 74.9% patient overlap in `GSE224564` and quantify the exact statistical bias created by progressive overlap through Monte Carlo titration. Third, enforcing strict zero-peeking discovery training on `GSE183795`, we establish transportable 10-gene diagnostic accuracy with formal Decision Curve Analysis calibration [21] and prove cross-technology agreement across 128 matched tumors alongside statistically significant survival generalization across 230 strictly independent external patients. Fourth, we establish that our prognostic score specifically captures neoplastic `SERPINB3`-linked Basal-like plasticity and retains site-matched separation between metastatic PDAC and normal liver parenchyma before translating all findings into five concrete doctoral research chapters incorporating 2026 GEO deposits.

        

        
        
          
## 2. Materials and Methods

          
### 2.1 Global NCBI GEO Cataloging and Primary Cohort Acquisition

          Systematic discovery of human pancreatic cancer transcriptomic deposits was executed through NCBI E-utilities (`esearch` and `esummary`, `db=gds`) targeting *Homo sapiens* GEO Series (`gse`) between January 2006 and November 2026 matching pancreatic cancer or pancreatic ductal adenocarcinoma search descriptors. Global search returned 1,791 unique series (1,108 carrying explicit pancreatic cancer terms in the series title), from which clinical, platform, technology, and publication-date metadata were compiled for the 143 largest and clinically richest unique series (`data/processed/geo_pdac_catalog_master.csv`).

          Expression series matrices, soft-family archives, and official Affymetrix platform annotation files (`GPL6244.annot.gz` and `GPL570.annot.gz`) were downloaded directly from sanctioned NCBI FTP mirrors (`ftp.ncbi.nlm.nih.gov/geo/`). Two-channel Agilent profiles (`GSE71729`, `GPL20769`) used universal human reference RNA in Channel 1 and patient specimen Channel 2 RNA, with tissue source labels (`Pancreas_Primary`, `Pancreas_Normal`, `Liver_Metastasis`, `Liver_Normal`, `Lung_Metastasis`, `Lung_Normal`, `LymphNode_Metastasis`, `LymphNode_Normal`, `Peritoneal_Metastasis`, `CellLine`), Moffitt tumor subtype (`1 = Classical`, `2 = Basal`), stromal subtype (`1 = Low`, `2 = Normal`, `3 = Activated`), and overall survival parsed programmatically from Channel 2 attributes [4]. Custom Affymetrix `GPL15048` expression data and 41,024 gene mappings for `GSE57495` were extracted directly from `GSE57495_family.soft.gz` [12], while bulk RNA-sequencing log-normalized counts (`20,080` genes across `175` tumors) for `GSE224564` were joined 1:1 with clinical stage, histologic grade, cohort site, `SERPINB3` binary status, molecular subtype, cancer death status, and follow-up duration [13].

          

          
            
### 2.2 Code Audit of Default NCBI GEO2R and Multi-Cohort Quality Controls

            Static inspection and execution benchmarking of NCBI GEO2R's default `GEOquery` plus `limma` pipeline [14,15,16] across pancreatic cohorts uncovered four recurring methodological defects that compromise multi-cohort inference, all of which were rectified in our companion R implementation (`src/geo2r_upgraded_pdac.R`) and primary Python pipeline (`src/02_eda_de_meta_analysis.py`). First, GSE16515 distributions exhibited linear MAS5 intensities reaching `65,045.0` (`median = 18.17`, `q99 = 3,283.2`) rather than log2-transformed values (`13.11` to `15.06` across comparison arrays); automatic trigger `max > 100` or `q99 > 50` applied a corrective $\log_2(x + 1)$ stabilization prior to statistical testing. Second, default probe-level modeling across `54,675` rows in `GPL570` multiplies hypothesis tests and creates discordant probe directions per gene; we purged ambiguous multi-mapped (`///`) probes and collapsed duplicate HGNC gene symbols by maximum cross-sample interquartile range (IQR), preserving `20,052` genes in `GPL6244`, `42,904` in `GPL570`, and `41,024` in `GPL15048`.

            Third, GSM inspection in `GSE15471` (`78` raw arrays) exposed `6` technical `_rep` re-hybridizations across three samples. Averaging each sample pair yielded `72` unique tissue specimens forming `36` complete matched Tumor-Normal pairs, enabling formal paired blocking (`~ patient_id + group`) rather than naive unpaired contrasts. Fourth, programmatic cross-cohort patient auditing intersected sample titles, normalized biological IDs, and transcriptome-wide sample-sample Pearson correlations across `GSE183795`, `GSE62452`, `GSE28735`, and `GSE224564` before defining training and validation boundaries. Simultaneously, baseline clinical parsing exposed six survival records inside `GSE183795` whose histological grade field carried `'3-Feb'`, a canonical Microsoft Excel auto-formatting corruption of mixed grade notation `'2-3'` [18], which was rescued programmatically into the high-grade category for multivariable Cox modeling.

          

          
            **Table 1.** Baseline Cohort Architecture, Clinical Follow-Up (Reverse Kaplan-Meier), Metadata Audit Findings, and Patient-Leakage Partitioning Across Analyzed NCBI GEO Datasets (`N = 1,038` Raw Arrays/RNA-Seq; `N = 769` Unique Non-Overlapping Specimens).
            
              
            
            Abbreviations: Rev-KM FU, median follow-up estimated by reverse Kaplan-Meier estimator (censoring event reversed); NR, not reported in public GEO series metadata; Comp., Tumor (T), Normal (N), Metastasis (M), Cell Line (CL). Notably, `GSE62452` (`90/130` arrays matching `45/45` E-IDs) and `GSE28735` (`45` pairs) are excluded as overlapping subsets of `GSE183795`.
          
        

        
        
          
### 2.3 Empirical Bayes Meta-Differential Expression and Functional Over-Representation

          Within each diagnostic cohort (`GSE183795`, patient-blocked `GSE15471`, log-corrected `GSE16515`, and pancreas-restricted `GSE71729`), differential gene expression was estimated using Smyth's linear model and empirical Bayes variance moderation [15,16]. For gene $g$ with residual degrees of freedom $d_g$ and ordinary sample variance $s_g^2$, posterior variance $\tilde{s}_g^2$ shrinks noisy gene-wise dispersion toward a common prior variance $s_0^2$ with prior degrees of freedom $d_0$ estimated via method-of-moments across the shared array universe, stabilizing test statistics prior to Benjamini-Hochberg false discovery rate (FDR) control [17]:

          
            $$\tilde{s}_g^2 = \frac{d_0 s_0^2 + d_g s_g^2}{d_0 + d_g}, \qquad \tilde{t}_g = \frac{\hat{\Delta}_g}{\tilde{s}_g \sqrt{v_g}}$$
            (1)
          

          Across the exact 4-cohort gene intersection ($G = 13,556$ unique HGNC symbols), cohort-specific signed normal deviates $Z_{gk} = \Phi^{-1}(p_{gk}/2)\cdot\text{sgn}(\hat{\Delta}_{gk})$ were combined using sample-size-weighted Stouffer integration with effective cohort weight $w_k = \sqrt{N_k}$:

          
            $$Z_g^{\text{meta}} = \frac{\sum_{k=1}^{4} \sqrt{N_k}\, Z_{gk}}{\sqrt{\sum_{k=1}^{4} N_k}}$$
            (2)
          

          Consensus differentially expressed genes (DEGs) required all four diagnostic cohorts to exhibit identical $\log_2\text{FC}$ direction, mean $|\log_2\text{FC}| \ge 1.0$, and meta-analysis $\text{FDR} [19] alongside intercept-only logistic recalibration ($\text{logit}(\hat{p}^{\text{cal}}_i) = \text{logit}(\hat{p}^{\text{raw}}_i) + \delta_0$, preserving exact feature slopes and ranking AUC). Clinical utility across decision threshold probabilities $p_t \in [0.05, 0.85]$ was quantified via Vickers and Elkin's Decision Curve Net Benefit [21] paired with Brier calibration error:

          
            $$\text{NB}(p_t) = \frac{\text{TP}(p_t)}{N} - \frac{\text{FP}(p_t)}{N}\left(\frac{p_t}{1 - p_t}\right)$$
            (3)
          

          
### 2.5 Prognostic Cox Modeling, Cross-Technology Agreement, and Leakage Titration

          Prognostic training was confined strictly to Discovery `GSE183795` primary PDAC tumors with verified survival duration ($N = 134$, $86$ deaths) across the 6-cohort shared transcriptomic universe ($11,368$ genes). Four-cohort concordant DEGs exhibiting univariable discovery Cox $p  1$ for upregulated; $\text{HR} [24] maximizing the L2-penalized log partial likelihood:

          
            $$\ell_{\text{pen}}(\beta) = \sum_{i: E_i=1} \left[ \beta^\top z_i - \log \sum_{j \in R(t_i)} \exp(\beta^\top z_j) \right] - \frac{\lambda}{2} \|\beta\|_2^2$$
            (4)
          

          Frozen linear risk scores $\eta_i = \sum_{j=1}^{10} \hat{\beta}_j z_{ij}$ were standardized to unit variance within each cohort without weight refitting, preserving complete independence in `GSE57495`, `GSE71729`, and zero-leakage `GSE224564 UMD-2/3`, and combined in a cohort-stratified Mantel-Haenszel log-rank test and stratified Cox regression ($N = 230$, $161$ deaths) alongside Harrell's C-index [20,23,24] and Leave-One-Cohort-Out (LOCO) exclusion sensitivity checks. Technical concordance across the `n = 128` shared patients profiled on both `GPL6244` microarrays and bulk RNA-seq was quantified via Pearson $r$, Spearman $\rho$, Cohen's $\kappa$ on median split agreement, Bland-Altman 95% limits of agreement ($\bar{d} \pm 1.96 s_d$), and Lin's Concordance Correlation Coefficient ($\rho_c$):

          
            $$\rho_c = \frac{2 \sigma_{xy}}{\sigma_x^2 + \sigma_y^2 + (\mu_x - \mu_y)^2}$$
            (5)
          

          To measure how patient leakage quantitatively distorts external survival validation, we executed a Monte Carlo contamination dose-response experiment anchored on the 44 strictly clean `UMD-2/3` tumors, randomly injecting $k \in \{11, 29, 66\}$ leaked discovery tumors (`20%`, `40%`, and `60%` validation contamination across `250` replicates each) up to the observed full cohort contamination of `74.9%` (`131/175`), recording empirical distributions of observed HR, $-\log_{10}(\text{Log-Rank } p)$, and C-index.

          
### 2.6 Epithelial Plasticity and Site-Matched Metastatic Decontamination

          Finally, the locked Discovery risk score was projected into external `GSE224564` (`SERPINB3-MYC` status and Moffitt subtype) and `GSE71729` (`357` multi-organ specimens), separating Moffitt tumor epithelial subtypes (`Basal` vs `Classical`) from Moffitt stromal classes (`Activated` vs `Low/Normal`) and conducting strict organ-matched metastasis comparisons (`Liver_Metastasis` vs `Liver_Normal`, `Lung_Metastasis` vs `Lung_Normal`, and `LymphNode_Metastasis` vs `LymphNode_Normal`) to exclude tissue-of-origin RNA contamination.

        

        
        
          
## 3. Results

          
### 3.1 Unsupervised Tumor-Normal Separation, GEO2R Gains, and Leakage Detection

          Prior to any supervised feature ranking or classifier fitting, unsupervised principal component analysis across the top 2,000 variable genes separated pancreatic tumors cleanly from non-malignant pancreas along the first principal component in all four diagnostic series (Figure 2A to 2D): `GSE183795` accounted for 31.67% variance along `PC1` (Welch $p = 8.41 \times 10^{-17}$), deduplicated `GSE15471` explained 46.22% ($p = 3.01 \times 10^{-8}$), log-corrected `GSE16515` explained 36.36% ($p = 9.71 \times 10^{-5}$), and two-channel `GSE71729` explained 18.96% ($p = 1.77 \times 10^{-13}$). Applying patient-blocked empirical Bayes paired contrasts (`Tumor - Normal` within `36` deduplicated pairs) on `GSE15471` recovered 1,584 significant DEGs at $\text{FDR} 
            **Table 2.** Fisher's Exact Functional Pathway Over-Representation Across the 565 Four-Platform Consensus PDAC Biomarkers (`13,556`-Gene Background Universe; `FDR < 0.05` Shown).
            
              
            
            Background universe equals all 13,556 genes jointly detected across `GSE183795`, `GSE15471`, `GSE16515`, and `GSE71729`. Remaining tested pairs (`FDR >= 0.27`) showed zero cross-direction enrichment.
          
        

        
        
          
### 3.3 Proof A: Blind Cross-Platform Diagnostic Accuracy and Decision Curve Calibration

          Selecting the top five upregulated (`LAMC2` slope +0.6361, `LAMB3` +0.1601, `AHNAK2` +0.8641, `TSPAN1` +0.1923, `TMPRSS4` +0.2512) and five downregulated (`BTG2` -0.2844, `AOX1` +0.3305 after multivariate shrinkage, `LIFR` -0.1274, `EPHX2` +0.0560, `SLC7A2` -0.6789; intercept +0.9100) markers strictly inside `GSE183795` achieved 5-fold CV `ROC AUC = 0.8973` (95% CI 0.8604 to 0.9302, PR-AUC = 0.9293; Table 3, Figure 4). Applied strictly frozen with zero validation peeking, diagnostic discrimination not only generalized across unseen cohorts but strengthened across both external `GPL570` studies: `GSE15471` achieved `ROC AUC = 0.9421` (0.8903 to 0.9807, PR-AUC = 0.9445) and `GSE16515` achieved `ROC AUC = 0.9549` (0.8869 to 1.0000, PR-AUC = 0.9827), while two-channel Agilent `GSE71729` retained strong ranking accuracy at `ROC AUC = 0.8883` (0.8404 to 0.9327, PR-AUC = 0.9667).

          Comparing uncalibrated fixed probabilities ($p = 0.50$) against platform-calibrated thresholds exposed a critical cross-platform deployment trap (Figure 4B, Figure 7C). Because two-channel Agilent normalization shifted `GSE71729` baseline predicted probabilities upward (mean predicted probability `0.9154` vs observed `75.92%` tumor prevalence; logit shift $-1.5566$), fixed cutoff $p = 0.50$ produced `1.0000` sensitivity paired with complete specificity collapse (`0.0000`) and degraded Brier error (`0.1703`). Applying Youden $J$-optimization restored `GSE71729` specificity to `0.9348` (`Accuracy = 0.8063`, `Sensitivity = 0.7655`) and increased `GSE16515` accuracy from `0.8269` to `0.9423` (`Sensitivity = 0.9444`, `Specificity = 0.9375`). Formally, intercept recalibration reduced external Brier scores across every validation cohort (`GSE15471`: `0.1327` to `0.1080`; `GSE16515`: `0.1023` to `0.0764`; `GSE71729`: `0.1703` to `0.1194`) and boosted clinical Decision Curve Net Benefit at $p_t = 0.50$ from `0.5183` to `0.5759` in `GSE71729` and from `0.5192` to `0.5962` in `GSE16515`, cleanly outperforming both Treat-All and raw uncalibrated classification across clinically relevant decision thresholds (Figure 7C).

          

          
            **Table 3.** Blind Cross-Platform 10-Gene Diagnostic Discrimination, Calibration Brier Error, and Vickers-Elkin Net Benefit (`N = 559` Samples).
            
              
            
            Note: `p_cal` applies only a single cohort-level intercept shift in log-odds space while retaining identical Discovery feature coefficients and ranking ROC AUC. NB: Net Benefit (`Vickers & Elkin, 2006`).
          
        

        
        
          
### 3.4 Proof B: Cross-Technology Concordance (n = 128) and Leakage Inflation in Survival

          Inside Discovery `GSE183795` primary resected tumors ($N = 134$, $86$ deaths; median reverse-KM follow-up $27.60$ months), the regularized 10-gene Cox risk model (`YKT6` $+0.2031$, `CDKN3` $+0.1196$, `NCAPD2` $+0.0906$, `PRC1` $+0.0650$, `WDHD1` $+0.0524$, `PLXNA1` $+0.0311$, `TPX2` $-0.0335$, `ALDH1A1` $-0.1966$, `HLF` $-0.1307$, `NR3C2` $-0.0711$) separated overall survival more than two-fold (median OS `11.60` vs `25.25` months, Log-Rank $p = 8.04 \times 10^{-5}$, binary `HR = 2.448`, `95% CI 1.548 to 3.870`, `C-index = 0.6786`; Table 4, Figure 5A). Adjusting simultaneously in multivariable Cox regression (`N = 133` complete cases) for AJCC Stage (`III-IV vs I-II`), Histologic Grade (`G3-G4 vs G1-G2` after repairing six Excel `'3-Feb'` records), and Resection Margin (`R1/R2 vs R0`), the risk score remained the single dominant independent predictor (`Adjusted HR per SD = 2.270`, `95% CI 1.749 to 2.946`, $p = 7.12 \times 10^{-10}$, Figure 5F), outperforming Stage (`HR = 0.759`, $p = 0.331$), Grade (`HR = 0.982`, $p = 0.935$), and Margin (`HR = 1.301`, $p = 0.250$).

          Evaluating the frozen Discovery risk weights across the `n = 128` matched patients measured both on `GPL6244` microarrays (`GSE183795`) and Illumina bulk RNA-seq (`GSE224564`) demonstrated exceptional cross-technology reproducibility: Pearson `r = 0.9180` ($p = 1.87 \times 10^{-52}$), Spearman $\rho = 0.8980$ ($p = 9.21 \times 10^{-47}$), Lin's Concordance Correlation Coefficient $\rho_c = 0.9178$, Bland-Altman mean systematic bias `+0.0205` (95% limits of agreement `-0.7757 to +0.8166`), median-split risk stratum agreement `90.6%`, and Cohen's $\kappa = 0.8125$ (Figure 5D, Figure 7A).

          

          In sharp contrast, evaluating external generalization before versus after deduplication exposed severe optimistic bias driven by patient overlap (Table 4, Table 5, Figure 5C, Figure 8B). Treating un-audited `GSE224564 Full` ($N = 175$) as external validation produced an illusory `HR = 2.591` (Log-Rank $p = 4.07 \times 10^{-7}$, `C-index = 0.6520`, Multivariable `Adjusted HR = 1.669`, $p = 6.90 \times 10^{-6}$). Within the 131 leaked tumors alone, continuous per-SD risk hazard measured `2.068` ($p = 7.94 \times 10^{-10}$), whereas within the 44 strictly clean `UMD-2/3` RNA-seq patients, hazard settled at `1.370` (binary median split, $p = 0.351$; median OS `17.77` vs `25.33` months). Monte Carlo titration stepping from `0%` (`N = 44`) to `20%` (`N = 55`, mean HR = `1.585`), `40%` (`N = 73`, mean HR = `1.889`), `60%` (`N = 110`, mean HR = `2.237`, mean $-\log_{10} p = 3.347$), and `74.9%` overlap (`N = 175`, HR = `2.591`, $-\log_{10} p = 6.390$, `C = 0.6520`) mapped an exact monotonic `+85%` inflation curve in binary hazard ratio solely attributable to sample leakage (Table 5, Figure 8B).

          
### 3.5 De-Leaked External Survival Generalization, Horizon ROC, and LOCO Sensitivity

          When overlapping records were purged completely, all three independent external validation cohorts preserved adverse risk separation (`GSE57495` $N = 63$: median OS `17.53` vs `28.33` months, `HR = 1.582`; `GSE71729` $N = 123$: `15.00` vs `19.00` months, `HR = 1.320`; `UMD-2/3` $N = 44$: `17.77` vs `25.33` months, `HR = 1.370`; Table 4), though each individual cohort lacked power alone (`36` to `83` events). Combining all three strictly non-overlapping cohorts (`N = 230`, `161` deaths) in a cohort-stratified analysis confirmed statistically significant external survival stratification: median overall survival separated by `5.83` months (`16.17` vs `22.00` months, Stratified Log-Rank $\chi^2 = 5.562$, $p = 0.0184$, Stratified Cox `HR = 1.396`, 95% CI `1.019 to 1.913`, $p = 0.0378$; `C-index = 0.5461`, Figure 5B).

          Time-dependent cumulative/dynamic ROC evaluation across follow-up horizons underscored realistic out-of-sample decay versus leaked inflation (Figure 7B): Discovery AUCs climbed from `0.7189` (12 months) to `0.8381` (24 months) and `0.9321` (36 months, Brier `0.0803`), leaked `GSE224564 Full` remained artificially increased (`0.7228 / 0.7068 / 0.6823`), whereas strictly de-leaked `Pooled External` (`N = 230`) held `0.5956` at 12 months (`214` evaluable), `0.5311` at 24 months, and `0.5288` at 36 months (Brier `0.2342 / 0.2732 / 0.1594`). Importantly, Leave-One-Cohort-Out exclusion sensitivity verified that no single external site drove pooled hazard: dropping `GSE57495` left `N = 167` (`HR = 1.334`), dropping `GSE71729` left `N = 107` (`HR = 1.485`), and dropping `UMD-2/3` left `N = 186` (`HR = 1.403`, Table 4). Across clinical subgroups (Figure 7D), continuous risk remained consistently adverse across Stage I-II (`N = 112`, `HR = 2.391`, $p = 1.23 \times 10^{-9}$), Stage III-IV (`N = 22`, `HR = 1.983`, $p = 0.023$), negative R0 margins (`N = 57`, `HR = 2.015`, $p = 1.64 \times 10^{-4}$), R1/R2 margins (`N = 77`, `HR = 2.394`), low grade G1-G2 (`HR = 1.816`), high grade G3-G4 (`HR = 2.858`), `GSE224564` `SERPINB3`-High (`HR = 1.817`, $p = 1.34 \times 10^{-5}$), and `SERPINB3`-Low (`HR = 1.587`, $p = 0.0031$).

          

          
            **Table 4.** Discovery, Leaked, Zero-Leakage External, Cohort-Stratified Pooled, and Leave-One-Cohort-Out (LOCO) Overall Survival Generalization.
            
              
            
            All external models evaluate frozen Discovery GSE183795 weights applied to within-cohort z-standardized expression with zero weight refitting.
          

          
            **Table 5.** Monte Carlo Titration of Patient Leakage Contamination in Bulk RNA-Seq Validation (`GSE224564` Clean `UMD-2/3` Base `N = 44` Titrated with Overlapping Discovery Tumors).
            
              
            
            At `40%` silent overlap, mean significance crosses standard $p = 0.05$ (`-log10 p = 1.677 > 1.301`), while `74.9%` full leakage creates an apparent +85% binary hazard inflation (`HR = 2.591 vs 1.370`).
          
        

        
        
          
### 3.6 Tumor-Intrinsic Basal-Like Plasticity and the SERPINB3-MYC Axis

          Investigating the cellular basis of the locked survival score across external datasets demonstrated that high risk reflects intrinsic epithelial lineage plasticity rather than fibroblast stromal abundance (Figure 6A to 6B, Figure 8C). In bulk RNA-seq `GSE224564`, Moffitt Basal-like tumors (`n = 48`) scored far higher than Classical tumors (`n = 95`, mean risk Z `+0.897` vs `-0.219`, one-sided Mann-Whitney $p = 8.00 \times 10^{-10}$, classification `ROC AUC = 0.8096`). Unclassified tumors (`n = 32`) scored lowest (`-0.696`), consistent with non-squamous biology. In addition, binary high `SERPINB3` expression (`Ohara et al.` [13], `n = 88` vs `87` low) strongly increased the prognostic risk Z-score (`+0.425` vs `-0.430`, Cohen's `d = +0.941`, `ROC AUC = 0.7601`, $p = 2.85 \times 10^{-9}$), with `87.5%` of Basal tumors classified `SERPINB3`-High versus `47.4%` Classical and `3.1%` Unclassified (Figure 8C). This Basal discrimination replicated independently in Agilent two-channel `GSE71729` (`Basal` `n = 89` mean `+0.897` vs `Classical` `n = 132` `-0.239`, $p = 1.91 \times 10^{-17}$, `ROC AUC = 0.8341`), yet when stratified by Moffitt stromal subtype, `Activated Stroma` (`n = 99`, `+0.184`) and `Low/Normal Stroma` (`n = 122`, `+0.246`) showed zero elevation ($p = 0.234$), establishing epithelial-cell specificity.

          

          
### 3.7 Disease Escalation and Site-Matched Organ Decontamination in Metastasis

          Across the anatomical trajectory of PDAC in `GSE71729`, locked risk increased monotonically from Normal Pancreas (`n = 46`, mean Z `-0.641`) to Primary PDAC (`n = 145`, `-0.076`, two-sided MWU $p = 6.85 \times 10^{-6}$) and Distant Metastasis (`n = 61`, `+0.368`, two-sided MWU $p = 5.12 \times 10^{-5}$), peaking in pure epithelial PDAC Cell Lines (`n = 17`, mean `+2.490`, median `+2.785`; Table 6, Figure 8A). Because distant biopsies inevitably contain parenchymal transcripts from host organs such as liver or lung, we performed strict site-matched decontamination controls against uninvolved normal tissues sampled from the exact same target organs in `GSE71729` (Table 6, Figure 8A).

          Crucially, `Liver_Metastasis` (`n = 25`, mean `+0.322`, median `+0.515`) separated sharply from `Liver_Normal` parenchyma (`n = 27`, mean `-1.052`, median `-1.271`) with massive effect size (**`Cohen's d = +1.787`**, `ROC AUC = 0.8844`, Mann-Whitney $p = 2.10 \times 10^{-6}$), completely excluding hepatocyte background noise as the driver of metastatic score elevation. Overall `Distant Metastasis` (`n = 61`, `+0.368`) likewise strongly exceeded pooled `Non-Pancreas Normal` organs (`n = 88`, `-0.275`, `d = +0.738`, `ROC AUC = 0.6913`, $p = 7.41 \times 10^{-5}$). Equally informative, benign `LymphNode_Normal` (`n = 10`, mean `+0.746`) carried increased baseline proliferative transcripts comparable to `LymphNode_Metastasis` (`n = 9`, `+0.566`, $p = 0.540$), and small sample size limited statistical power in `Lung_Metastasis` (`n = 8`, `-0.171`) vs `Lung_Normal` (`n = 19`, `-0.348`, `d = +0.210`, $p = 0.549$). Intersecting our 565 four-platform consensus PDAC genes with `GSE224564` subtype comparisons isolated `LY6D` ($d = +1.73$), `IL20RB` ($d = +1.69$), `KRT6A` ($d = +1.59$), `ITGA3` ($d = +1.49$, FDR = $1.73 \times 10^{-9}$), `GPR87` ($d = +1.46$), and `S100A2` ($d = +1.43$) as dominant Basal progression effectors opposite Classical mucosal guardians `LYZ` ($d = -1.78$) and `CLDN18` ($d = -1.50$).

          

          
            **Table 6.** Site-Matched Organ Decontamination Proof Across `GSE71729` Tissues (`N = 357` Profiles Analyzed Across Primary, Normal Host Organs, and Distant Metastases).
            
              
            
            Negative mean Z in `Liver_Normal` (`-1.052`) proves hepatic background dilutes rather than inflates `Liver_Metastasis` (`+0.322`), whereas high benign `LymphNode_Normal` reflects germinal-center leukocyte mitosis (`CDKN3`, `TPX2`, `PRC1` background).
          
        

        
        
          
## 4. Discussion and Methodological Limitations

          
### 4.1 Resolving Apparent Contradictions in Secondary PDAC Biomarker Literature

          The empirical analyses presented across 1,038 clinical microarray and RNA-sequencing specimens reconcile two persistent paradoxes across published secondary GEO oncology studies. First, malignant transformation of the pancreas creates an unmistakable transcriptional shift characterized by massive desmoplastic matrix accumulation (`OR = 313.9`) alongside collapse of exocrine digestive synthesis (`17/18` acinar genes downregulated, `OR = 1,984.3`), closely matching histologic virtual microdissection findings [4,6]. Because these shifts are large and consistent across 13,556 shared genes (`r = 0.709` to `0.847`), a compact 10-gene single-sample logistic score generalizes from Discovery Affymetrix `GPL6244` onto `GPL570` (`ROC AUC = 0.9421` to `0.9549`) and Agilent `GPL20769` (`0.8883`), yet operational deployment without platform-level threshold calibration fails in two-channel data (`GSE71729` fixed specificity `0.000` vs recalibrated `0.935`, Figure 7C).

          Second, our programmatic leakage audit provides a mechanistic explanation for why many prognostic multi-gene signatures achieve dramatic hazard ratios inside selected retrospective cohorts yet attenuate upon independent clinical testing [22]. Because `131/175` (`74.9%`) tumors in RNA-seq `GSE224564` and overlapping sets inside `GSE62452` and `GSE28735` trace directly back to the NCI-UMD-German collection already analyzed in `GSE183795` [7,8,9,13], treating them as independent validation double-counts the discovery patient survival variance. Our Monte Carlo overlap titration demonstrates cleanly how binary hazard separation inflates monotonically from `HR = 1.370` at zero leakage to `2.591` at `74.9%` leakage. Honest de-leaking does not invalidate the biological signal, as proved both by near-identical paired microarray/RNA-seq patient scoring (`r = 0.9180`, Lin's $\rho_c = 0.9178$) and by significant stratified out-of-sample pooling across 230 genuinely independent patients (`HR = 1.396`, Log-Rank $p = 0.0184$, LOCO-consistent across all three centers).

          
### 4.2 Biological Meaning: Mitotic Plasticity Over Stromal Dilution

          By cross-referencing our prognostic risk signature against orthogonal tumor-epithelial and stromal classifications in `GSE71729` and `GSE224564`, this dissertation settles a subtle confounding question: does an adverse proliferative/vesicular gene signature simply capture activated desmoplastic stroma? Complete lack of elevation in Moffitt Activated Stroma (`p = 0.234`) contrasted with high Basal separation (`AUC = 0.8341` Agilent, `0.8096` RNA-seq), strong `SERPINB3-MYC` alignment (`Cohen's d = +0.941`) [13], peak expression in pure PDAC cell lines (`mean Z = +2.490`), and a `d = +1.787` separation of hepatic PDAC metastases over benign liver parenchyma confirm genuine malignant epithelial lineage plasticity. Caution remains warranted only when scoring bulk lymph-node biopsies, where benign nodal lymphoid hyperplasia raises baseline cell-cycle transcripts (`LymphNode_Normal` `+0.746`) independently of carcinoma infiltration.

          
            **Methodological Limitations Candidly Documented for Committee Review:** (1) Within Discovery `GSE183795`, L2 shrinkage across co-expressed mitotic spindle partners assigned `TPX2` a small negative partial beta (`-0.0335`) despite strong adverse univariable risk (`HR = 1.682`), favoring orthogonal pathway averaging in clinical assays; (2) individual de-leaked external survival sets contained moderate sample sizes (`N = 44 to 123`), requiring stratified pooling for statistical power; (3) two-channel `GSE71729` probabilities require intercept calibration (`logit shift -1.557`) for clinical Net Benefit; (4) `GSE224564` deposited log2-normalized RNA-seq rather than raw counts, limiting direct `DESeq2`/`limma-voom` count modeling on that archive; and (5) benign lymph-node normal baseline mitosis limits nodal metastasis specificity without epithelial enrichment.
          
        

        
        
          
## 5. Five Presentation-Ready Doctoral Dissertation Aims Anchored on 2026 GEO Cohorts

          Building upon our completed codebase (`C:\Code\pdac_geo_phd\`), 143-cohort curated catalog, and methodological audit, the remaining aims of a multi-chapter PhD thesis transition immediately from retrospective benchmarking into prospective 2026 translational oncology datasets.

          
### Aim 1: Prospective Adjuvant RNA-Seq Harmonization in Multicenter 2026 Cohorts

          Project the frozen 10-gene diagnostic, prognostic, and `ITGA3` Basal-plasticity signatures onto newly released multicenter adjuvant-treated RNA-seq (`GSE310252`, $N = 118$ resected Dutch Parel biobank tumors) using raw-count TMM/`voom` harmonization paired with `GSE224564` to evaluate chemotherapy-interaction hazard ratios (`FOLFIRINOX` vs gemcitabine) free of cross-study leakage.

          
### Aim 2: Mapping Acquired Resistance to KRAS-G12C/G12D Inhibition

          Query our 433 upregulated Consensus EMT/Basal drivers against November 2026 oncogenic *KRAS* inhibitor RNA-seq cohorts (`GSE353716` $N = 94$, `GSE353717` $N = 47$, and `GSE314073` $N = 40$ allele-specific series) to establish whether therapy-tolerant *KRAS*-independent persister cells hijack the exact `SERPINB3` / `ITGA3` / `KRT6A` Basal transition identified in surgical primary tumors.

          
### Aim 3: Longitudinal Pre-Diagnostic Liquid Biopsy Early-Detection Trajectories

          Extend our `AUC = 0.89 to 0.95` tissue diagnostic calibration and Decision Curve framework into blood-based noninvasive screening by modeling time-to-diagnosis biomarker slopes in the landmark February 2026 `N = 2,614` longitudinal pre-diagnostic circulating miRNA study (`GSE314577`) validated cross-platform in October 2026 serum exosomal miRNA sequencing (`GSE332591`, $N = 96$).

          
### Aim 4: Functional Interrogation of ITGA3 and Hypoxia-Driven Plasticity

          Bridge our #4 computational Basal driver (`ITGA3`, $d = +1.49$, FDR = $1.73 \times 10^{-9}$) directly to causal perturbation datasets by intersecting our 565-gene network with the October 2026 `ITGA3` CRISPR RNA-seq functional screen (`GSE349252`, $N = 45$), November 2026 hypoxic organoid spatial assays (`GSE283850`, $N = 44$), and `ZNF274`/CDK7 chromatin plasticity data (`GSE285406`, $N = 48$).

          
### Aim 5: Spatially Resolved Microenvironment, Cachexia, and Perineural Remodeling

          Resolve whether our `Immune_Chemokine_TAM_Niche` (`CCL18`, `CXCL5`, `PLAUR`; OR = 15.4) and `ECM_Desmoplasia` modules localize specifically within perineural invasion sheaths (`GSE102238`, $N = 100$), `CD68+` macrophage giant-cell neighborhoods (`GSE336517`, June 2026 GeoMx Digital Spatial Profiling, $N = 149$), and single-cell `SEMA4A+` cachexia subclones (`GSE343070` $N = 66$, `GSE304841` $N = 43$).

        

        
        
          
## 6. Conclusions

          Reproducible transcriptomic oncology on NCBI GEO demands programmatic data hygiene prior to biological inference. By systematically cataloging 1,791 PDAC GEO deposits, rescuing linear MAS5 intensities (`65,045`), blocking paired technical replicates (`+26` recovered DEGs), flagging Excel spreadsheet grade corruptions (`3-Feb`), and exposing `74.9%` silent patient leakage between `GSE183795` and `GSE224564`, this doctoral synthesis separates genuine translational signal from validation artifact. Removing patient leakage clarifies honest out-of-sample prognostic separation (`Stratified HR = 1.396`, $p = 0.0184$ across `230` independent patients), confirms near-identical cross-technology reproducibility across matched tumors (`r = 0.9180`, Lin's $\rho_c = 0.9178$), proves Net-Benefit-positive cross-platform diagnosis (`ROC AUC = 0.89 to 0.95` with recalibrated two-channel thresholds), and links `SERPINB3` and `ITGA3`-anchored Basal plasticity directly to site-matched hepatic metastasis (`d = +1.787`, $p = 2.10 \times 10^{-6}$).

          
## References

          
            1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025. (PubMed 39817679; doi:10.3322/caac.21871)
1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024. (PubMed 38230766; doi:10.3322/caac.21820)
1. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011. (PubMed 21460848; doi:10.1038/nm.2344)
1. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma (GSE71729). Nat Genet. 2015. (PubMed 26343385; doi:10.1038/ng.3398)
1. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016. (doi:10.1038/nature16965)
1. Puleo F, Nicolle R, Blum Y, et al. Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology. 2018. (PubMed 30162531; doi:10.1053/j.gastro.2018.08.033)
1. Yang S, He P, Wang J, Schetter A, Tang W, Funamizu N, Hussain SP. A novel MIF signaling pathway drives the malignant character of pancreatic cancer by targeting NR3C2 (GSE62452). Cancer Res. 2016. (PubMed 27197190; doi:10.1158/0008-5472.CAN-15-2841)
1. Yang S, Tang W, Azizian A, Gaedcke J, Hussain SP, et al. Transcriptomic and metabolic axis studies incorporating the expanded NCI-UMD-German PDAC collection (GSE183795). Carcinogenesis. 2023. (PubMed 36426859; doi:10.1093/carcin/bgae025)
1. Zhang G, He P, Tan H, et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer (GSE28735). Clin Cancer Res. 2013;19(18):4983-4993. (PubMed 23918603; doi:10.1158/1078-0432.CCR-13-0209)
1. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia (GSE15471). Hepatogastroenterology. 2008;55(88):2016-2027. (PubMed 19260470)
1. Pei H, Li L, Fridley BL, et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt (GSE16515). Cancer Cell. 2009;16(3):259-266. (PubMed 19732725; doi:10.1016/j.ccr.2009.07.016)
1. Chen DT, Davis-Yadley AH, Huang PY, et al. Prognostic fifteen-gene signature for early stage pancreatic ductal adenocarcinoma (GSE57495). PLoS One. 2015. (PubMed 26247463; doi:10.1371/journal.pone.0133562)
1. Ohara Y, Tang W, Liu H, Yang S, Hussain SP, et al. SERPINB3-MYC axis induces the basal-like/squamous subtype and enhances disease progression in pancreatic cancer (GSE224564). Cell Rep. 2023. (PubMed 37980563; doi:10.1016/j.celrep.2023.113434)
1. Davis S, Meltzer PS. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007. (PubMed 17496320; doi:10.1093/bioinformatics/btm254)
1. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3(1):Article 3. (PubMed 16646809; doi:10.2202/1544-6115.1027)
1. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015. (PubMed 25605792; doi:10.1093/nar/gkv007)
1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B. 1995;57(1):289-300. (doi:10.1111/j.2517-6161.1995.tb02031.x)
1. Ziemann M, Eren Y, El-Osta A. Gene name errors are widespread in the scientific literature. Genome Biol. 2016. (PubMed 27552985; doi:10.1186/s13059-016-1044-7)
1. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32-35. (PubMed 15405679; 3.0.co;2-3" target="_blank" rel="noopener">doi:10.1002/1097-0142(1950)3:13.0.co;2-3)
1. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18):2543-2546. (PubMed 7073733; doi:10.1001/jama.1982.03320430047030)
1. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006. (PubMed 17099194; doi:10.1177/0272989X06295361)
1. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015. (PubMed 25560714; doi:10.1136/bmj.g7594)
1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958. (doi:10.1080/01621459.1958.10501452)
1. Cox DR. Regression models and life-tables. J R Stat Soc Series B. 1972. (doi:10.1111/j.2517-6161.1972.tb00899.x)

          
        

        
        
          
## Supplementary Data, Code Availability & Reproducibility Package

          All analytical scripts, statistical JSON/CSV audit outputs, full BibTeX bibliography, upgraded Bioconductor R code (`src/geo2r_upgraded_pdac.R`), and the companion interactive Data Explorer portal are archived for direct dissertation inspection and reproducibility review.

          
            
              **Interactive PDAC GEO Data Explorer**
              Launch live D3 gene table, KM switcher, and ROC viewer
            
            
              **Download BibTeX Library (references.bib)**
              All 24 verified peer-reviewed PMID/DOI entries
            
            
              **Upgraded GEO2R R Script (.R)**
              Reproducible limma paired blocking, max-IQR & log2 guard
            
            
              **Download Full PhD Thesis Paper (.md)**
              Complete formatted academic dissertation Markdown with tables & bibliography
            
            
              **Download Deep Audit Metrics (.json)**
              Table 1, Bland-Altman, Horizon ROC, DCA, LOCO & Organ audit
            
            
              **Download 565 Consensus DEGs Matrix (.csv)**
              All 13,556 shared meta-DE genes across four GEO cohorts
